Anticoagulants help moderately ill COVID-19 patients, study finds

Date:
August 20, 2021
Source:
UT Southwestern Medical Center
Summary:
Moderately ill patients hospitalized with COVID-19 have
better chances of survival if treated with therapeutic-dose
anticoagulation, according to a new study.



FULL STORY ========================================================================== Moderately ill patients hospitalized with COVID-19 have better chances
of survival if treated with therapeutic-dose anticoagulation, according
to an international study involving 121 sites, including UT Southwestern Medical Center.


========================================================================== Moderately ill COVID-19 patients treated with therapeutic-dose
anticoagulation with unfractionated or low molecular-weight heparin
were 27% less likely to need cardiovascular respiratory organ support
such as intubation, said Ambarish Pandey, M.D., Assistant Professor of
Internal Medicine at UT Southwestern, who served as site investigator
and co-author of the study reported in The New England Journal of
Medicine. Moderately ill patients had a 4% increased chance of survival
until discharge without requiring organ support with anticoagulants,
according to the study involving 2,200 patients.

"The 4% increase in survival to discharge without needing organ support represents a very meaningful clinical improvement in these patients,"
said Dr.

Pandey, a Texas Health Resources Clinical Scholar who specializes
in preventive cardiology and heart failure with preserved ejection
fraction. "If we treat 1,000 patients who are hospitalized with COVID-19
with moderate illness, an additional 40 patients would have meaningful improvement in clinical status." Participating platforms for the
study, which defined moderately ill patients as those who did not need intensive care unit-level support, included Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC); A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a);
and Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). Comparisons between the three platforms are provided in the supplementary appendix, available with
the full text of the article at NEJM.org.

A parallel study in The New England Journal of Medicine found that
therapeutic- dose anticoagulation did not help severely ill patients.

========================================================================== Story Source: Materials provided by UT_Southwestern_Medical_Center. Note: Content may be edited for style and length.


========================================================================== Journal References:
1. The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic
Anticoagulation with Heparin in Noncritically Ill Patients with
Covid-19.

The New England Journal of Medicine, Aug. 4, 2021; DOI: 10.1056/
NEJMoa2105911
2. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic
Anticoagulation with Heparin in Critically Ill Patients with
Covid-19.

The New England Journal of Medicine, Aug. 4, 2021; DOI: 10.1056/
NEJMoa2103417 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/08/210820093357.htm

--- up 15 weeks, 22 hours, 45 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)